ArticleBritish journal of cancer2012
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Management of drainage for malignant ascites in gynaecological cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Diagnostic and therapeutic abdominal paracentesis.The Medical journal of Australia · 2023Article
- An Academic Hospitalist-Run Outpatient Paracentesis Clinic.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.Journal for immunotherapy of cancer · 2020Article
- Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites.BMC palliative care · 2019Article
- HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect.Journal of ovarian research · 2018Article
- Relationship between infiltrating lymphocytes in cancerous ascites and dysfunction of Cajal mesenchymal cells in the small intestine.International journal of clinical and experimental pathology · 2018Article
- Drainage of malignant ascites: patient selection and perspectives.Cancer management and research · 2017Review
- The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer.Expert review of quality of life in cancer care · 2016Article
- Automated low flow pump system for the treatment of refractory ascites: a single-center experience.Langenbeck's archives of surgery · 2015Article
- A survey of treatment approaches of malignant ascites in Germany and Austria.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundParacentesis for malignant ascites is usually performed as an in-patient procedure, with a median length of stay (LoS) of 3-5 days, with intermittent clamping of the drain due to a perceived risk of hypotension. In this study, we assessed the safety of free drainage and the feasibility and cost-effectiveness of daycase paracentesis.
methodOvarian cancer admissions at Hammersmith Hospital between July and October 2009 were audited (Stage 1). A total of 21 patients (Stage 2) subsequently underwent paracentesis with free drainage of ascites without intermittent clamping (October 2010-January 2011). Finally, 13 patients (19 paracenteses, Stage 3), were drained as a daycase (May-December 2011).
resultsOf 67 patients (Stage 1), 22% of admissions and 18% of bed-days were for paracentesis, with a median LoS of 4 days. In all, 81% of patients (Stage 2) drained completely without hypotension. Of four patients with hypotension, none was tachycardic or symptomatic. Daycase paracentesis achieved complete ascites drainage without complications, or the need for in-patient admission in 94.7% of cases (Stage 3), and cost £954 compared with £1473 for in-patient drainage.
conclusionsFree drainage of malignant ascites is safe. Daycase paracentesis is feasible, cost-effective and reduces hospital admissions, and potentially represents the standard of care for patients with malignant ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.